This is a delivery order awarded by the Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) under the Biologics Effectiveness and Safety (BEST) Initiative contract. The $9,854,162.67 time and materials contract is for the development of new and innovative methods for automated reporting for the FDA's Center for Biologics Evaluation and Research (CBER). The contract supports the BEST Initiative, which focuses on developing advanced methods for tracking and reporting on the safety and effectiveness of FDA-regulated biologics. There is no set-aside designation for this award, which has a completion date of September 26, 2024. As a large, established technology provider, IBM has a strong track record of delivering IT solutions and services to federal agencies, including the FDA and other civilian and defense organizations.
Generated 7/9/24, 1:41 PM